131 related articles for article (PubMed ID: 17579182)
1. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia.
Lilleri D; Gerna G; Furione M; Bernardo ME; Giorgiani G; Telli S; Baldanti F; Locatelli F
Blood; 2007 Oct; 110(7):2757-60. PubMed ID: 17579182
[TBL] [Abstract][Full Text] [Related]
2. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
3. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.
Gerna G; Lilleri D; Caldera D; Furione M; Zenone Bragotti L; Alessandrino EP
Bone Marrow Transplant; 2008 May; 41(10):873-9. PubMed ID: 18209721
[TBL] [Abstract][Full Text] [Related]
4. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
[TBL] [Abstract][Full Text] [Related]
5. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial.
Gerna G; Lilleri D; Baldanti F; Torsellini M; Giorgiani G; Zecca M; De Stefano P; Middeldorp J; Locatelli F; Revello MG
Blood; 2003 Jun; 101(12):5053-60. PubMed ID: 12586622
[TBL] [Abstract][Full Text] [Related]
6. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
Gerna G; Lilleri D; Zecca M; Alessandrino EP; Baldanti F; Revello MG; Locatelli F
Haematologica; 2005 Apr; 90(4):526-33. PubMed ID: 15820949
[TBL] [Abstract][Full Text] [Related]
7. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients.
Gerna G; Baldanti F; Lilleri D; Parea M; Alessandrino E; Pagani A; Locatelli F; Middeldorp J; Revello MG
J Clin Microbiol; 2000 May; 38(5):1845-53. PubMed ID: 10790111
[TBL] [Abstract][Full Text] [Related]
8. CMV antigenemia and quantitative viral load assessments in hematopoietic stem cell transplant recipients.
Cardeñoso L; Pinsky BA; Lautenschlager I; Aslam S; Cobb B; Vilchez RA; Hirsch HH
J Clin Virol; 2013 Feb; 56(2):108-12. PubMed ID: 23146665
[TBL] [Abstract][Full Text] [Related]
9. A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients.
Lehto JT; Lemström K; Halme M; Lappalainen M; Lommi J; Sipponen J; Harjula A; Tukiainen P; Koskinen PK
Transpl Int; 2005 Dec; 18(12):1318-27. PubMed ID: 16297050
[TBL] [Abstract][Full Text] [Related]
10. [Prevalence of human herpesvirus-6 in allogeneic hematopoietic stem cell transplant recipients in correlation with cytomegalovirus infection].
Wang LR; Dong LJ; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1204-9. PubMed ID: 17204195
[TBL] [Abstract][Full Text] [Related]
11. Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide.
Huntley D; Giménez E; Pascual MJ; Hernández-Boluda JC; Gago B; Vázquez L; Piñana JL; García M; Pérez A; Serrano D; Hernández M; Albert E; Solano C; Navarro D
Transpl Infect Dis; 2020 Feb; 22(1):e13206. PubMed ID: 31677215
[TBL] [Abstract][Full Text] [Related]
12. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
[TBL] [Abstract][Full Text] [Related]
13. ELISPOT assay of interferon-γ secretion for evaluating human cytomegalovirus reactivation risk in allo-HSCT recipients.
Liang H; Xia J; Zhang R; Yang B; Wu J; Gui G; Huang Y; Chen X; Yang R; Wang H; Gong S; Fan J
J Med Virol; 2021 Nov; 93(11):6301-6308. PubMed ID: 34076905
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation.
Gerna G; Lilleri D; Callegaro A; Goglio A; Cortese S; Stroppa P; Torre G
Transplantation; 2008 Jul; 86(1):163-6. PubMed ID: 18622294
[TBL] [Abstract][Full Text] [Related]
15. Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia.
Gerna G; Zipeto D; Parea M; Percivalle E; Zavattoni M; Gaballo A; Milanesi G
Mol Cell Probes; 1991 Oct; 5(5):365-74. PubMed ID: 1665208
[TBL] [Abstract][Full Text] [Related]
16. Monitoring human cytomegalovirus infection in transplant recipients.
Baldanti F; Lilleri D; Gerna G
J Clin Virol; 2008 Mar; 41(3):237-41. PubMed ID: 18203657
[TBL] [Abstract][Full Text] [Related]
17. [Detection of cytomegalovirus antigens and virus DNA in the peripheral blood after organ transplantation].
Xiao Y; Shi K; Mao X
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Sep; 13(3):287-90. PubMed ID: 12569767
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients.
Gerna G; Percivalle E; Baldanti F; Sarasini A; Zavattoni M; Furione M; Torsellini M; Revello MG
New Microbiol; 1998 Jul; 21(3):293-308. PubMed ID: 9699213
[TBL] [Abstract][Full Text] [Related]
19. Human cytomegalovirus (HCMV) leukodnaemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection.
Gerna G; Zavattoni M; Baldanti F; Sarasini A; Chezzi L; Grossi P; Revello MG
Transplantation; 1998 May; 65(10):1378-85. PubMed ID: 9625022
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]